SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Centocor ( CNTO )
CNTO 0.000010000.0%Mar 7 3:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bob Ponko who wrote (34)11/11/1996 4:52:00 PM
From: Thean   of 965
 
I think the cost effectiveness data from the EPILOG is the key missing link for CNTO stock price. Until this data is published, not too many doctors and administrators in the hospitals are willing to stick their necks out and call for the wider use of ReoPro. I think current price has already factored in the company anticipated filing for expanded indications. CNTO has been volatile lately and this could well be due to short term portfolio shuffling by the big players. No doubt CNTO will head higher over the long haul but near term CNTO may not be as attractive a Biotech play as other companies such as Biogen.

Bob, do you have any feel for the best timing for getting FDA approval for the expanded Reopro indication once they file?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News